tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ANTX Stock Latest News

AN2 Therapeutics Reports Q3 2025 Financial Results
Company AnnouncementsAN2 Therapeutics Reports Q3 2025 Financial Results
20d ago
ANTX
AN2 Therapeutics reports Q3 EPS (31c), two estimates (22c)
PremiumThe Fly
AN2 Therapeutics reports Q3 EPS (31c), two estimates (22c)
21d ago
ANTX
AN2 Therapeutics announces tuberculosis collaboration agreement with GSK
PremiumThe Fly
AN2 Therapeutics announces tuberculosis collaboration agreement with GSK
23d ago
GSK
ANTX
AN2 Therapeutics Advances with Phase 1 Trial of Oral AN2-502998
PremiumCompany Announcements
AN2 Therapeutics Advances with Phase 1 Trial of Oral AN2-502998
1M ago
ANTX
AN2 Therapeutics, Inc.: Hold Rating Amid Early-Stage Progress and Financial Uncertainty
PremiumRatings
AN2 Therapeutics, Inc.: Hold Rating Amid Early-Stage Progress and Financial Uncertainty
4M ago
ANTX
AN2 Therapeutics Reports Improved Financial Results
PremiumCompany AnnouncementsAN2 Therapeutics Reports Improved Financial Results
4M ago
ANTX
AN2 Therapeutics reports Q2 EPS (21c) vs. (48c) last year
Premium
The Fly
AN2 Therapeutics reports Q2 EPS (21c) vs. (48c) last year
4M ago
ANTX
AN2 Therapeutics completes dosing in cohort in AN2-502998 trial
Premium
The Fly
AN2 Therapeutics completes dosing in cohort in AN2-502998 trial
4M ago
ANTX
AN2 Therapeutics, DNDi collaborate on development of AN2-502998
PremiumThe Fly
AN2 Therapeutics, DNDi collaborate on development of AN2-502998
4M ago
ANTX
AN2 Therapeutics completes 200-patient observational study in acute melioidosis
PremiumThe Fly
AN2 Therapeutics completes 200-patient observational study in acute melioidosis
5M ago
ANTX
AN2 Therapeutics Enhances Financial Flexibility with Share Exchange
PremiumCompany Announcements
AN2 Therapeutics Enhances Financial Flexibility with Share Exchange
6M ago
8K
ANTX
AN2 Therapeutics Unveils Updated Investor Presentation
PremiumCompany Announcements
AN2 Therapeutics Unveils Updated Investor Presentation
6M ago
8K
ANTX
AN2 Therapeutics Elects New Directors at Annual Meeting
PremiumCompany AnnouncementsAN2 Therapeutics Elects New Directors at Annual Meeting
6M ago
8K
ANTX
AN2 Therapeutics, Inc.: Hold Rating Amid Strategic Shift and Financial Resilience
Premium
Ratings
AN2 Therapeutics, Inc.: Hold Rating Amid Strategic Shift and Financial Resilience
7M ago
ANTX
AN2 Therapeutics reports Q1 EPS (35c) vs. (56c) last year
Premium
The Fly
AN2 Therapeutics reports Q1 EPS (35c) vs. (56c) last year
7M ago
ANTX
AN2 Therapeutics price target lowered to $2 from $5 at Citizens JMP
PremiumThe Fly
AN2 Therapeutics price target lowered to $2 from $5 at Citizens JMP
7M ago
ANTX
AN2 Therapeutics Faces Setback in Phase 3 Study
PremiumCompany Announcements
AN2 Therapeutics Faces Setback in Phase 3 Study
7M ago
8K
ANTX
AN2 Therapeutics reports data fro previously terminated EBO-301 Study
PremiumThe Fly
AN2 Therapeutics reports data fro previously terminated EBO-301 Study
7M ago
ANTX
AN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Strong Financial Position
PremiumRatings
AN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Strong Financial Position
8M ago
ANTX
AN2 Therapeutics Reports 2024 Financials and Pipeline Progress
PremiumCompany AnnouncementsAN2 Therapeutics Reports 2024 Financials and Pipeline Progress
8M ago
ANTX
AN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Stable Financial Outlook
Premium
Ratings
AN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Stable Financial Outlook
8M ago
ANTX
AN2 Therapeutics, Inc.: Promising Future with Strong Financial Health and Strategic Advancements
Premium
Ratings
AN2 Therapeutics, Inc.: Promising Future with Strong Financial Health and Strategic Advancements
8M ago
ANTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >